VolitionRx Limited (NYSE:VNRX) Insider Acquires $24,903.87 in Stock

VolitionRx Limited (NYSE:VNRXGet Free Report) insider Jacob Vincent Micallef purchased 43,691 shares of VolitionRx stock in a transaction that occurred on Monday, December 9th. The shares were bought at an average price of $0.57 per share, with a total value of $24,903.87. Following the completion of the transaction, the insider now owns 394,352 shares of the company’s stock, valued at $224,780.64. This represents a 12.46 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

VolitionRx Price Performance

VolitionRx stock traded down $0.01 during trading on Tuesday, reaching $0.58. The company had a trading volume of 1,915,668 shares, compared to its average volume of 164,664. The firm’s 50-day simple moving average is $0.69 and its 200 day simple moving average is $0.67. VolitionRx Limited has a 1-year low of $0.43 and a 1-year high of $1.23.

Institutional Trading of VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC raised its position in VolitionRx Limited (NYSE:VNRXFree Report) by 78.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

Wall Street Analyst Weigh In

VNRX has been the subject of several recent research reports. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of VolitionRx in a report on Tuesday. StockNews.com started coverage on shares of VolitionRx in a research report on Friday. They issued a “sell” rating for the company. Finally, Benchmark restated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

View Our Latest Stock Report on VolitionRx

VolitionRx Company Profile

(Get Free Report)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

See Also

Insider Buying and Selling by Quarter for VolitionRx (NYSE:VNRX)

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.